



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

November 14th, 2016

To,

The Secretary,
The Stock Exchange, Mumbai
Phiroze Jeejeebhoy Towers,
Dalal Street, MUMBAI - 400 001

The Secretary,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex,
Bandra (E), MUMBAI - 400 051.

The Secretary,
The Stock Exchange, Ahmedabad,
Kamdhenu Complex,
Opp : Sahajanand College,
Panjarpole, Ahmedabad - 380 015.

COMPANY CODE NO: 537291

Sub: Submission of information under Regulation 33(3)(a) of the SEBI (LORD) Regulations, 2015.

Dear Sir,


Please find enclosed herewith Quarterly Unaudited Results along with Limited Review Report which is certified with Statutory Auditor for the quarter ended September 30th, 2016.

The above information is being provided to you under Regulation 33(3)(a) of the SEBI (LORD) Regulations, 2015.

This is for your information and record purpose.

Thanking You.

Yours faithfully,
For Nath Bio-Genes (India) Limited,


Authorised Signatory



Gautam N Associates

Chartered Accountants


30, GNA House, Behind ABC Complex,
Manmandir Travels Lane, Adalat Road, Aurangabad-431001

LIMITED REVIEW REPORT

To
The Board of Directors of
NATH BIO-GENES (INDIA) LIMITED.

1. We have reviewed the accompanying statement of unaudited financial results for the quarter ended 30th September 2016 (the Statement) of NATH BIO-GENES (INDIA) LIMITED (the Company) except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoters Group Shareholding', which have been traced from the disclosure made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material mis-statement. A review is limited primarily to enquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard -25 "Interim Financial Reporting", specified under the Companies Act, 1956 (which are deemed to be applicable as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation -33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material mis-statement.

For Gautam N Associates
Chartered Accountants
FRN : 103117W


(Gautam Nandawat)
Partner
M N :032742



Place: Aurangabad
Dated: 14th November, 2016



Nath Bio-Genes (I) Ltd. (CIN L01110MH1901PLC072842)

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30/09/2016

		Three Months Ended			Six Months Ended		Year Ended
		30/09/2016 Unaudited	30/06/2016 Unaudited	30/09/2015 Unaudited	30/09/2016 Unaudited	30/09/2015 Unaudited	31/03/2016 Audited
		Rs in Lacs					
1	Net Sales / Income from operations	1645.30	8432.99	394.96	10078.29	11049.55	16210.59
2	Expenses	(787.01)	1764.61	55.66	977.60	65.33	(2442.00)
	a) Changes in Inventory	1410.79	1981.45	193.07	3392.24	4172.99	7795.86
	b) Cost of Material Consumed	397.94	443.78	354.75	831.72	846.67	1363.44
	c) Employee benefit expense	241.57	2063.03	119.01	2304.60	3268.63	5032.64
	d) Selling & Distribution Expenses	75.34	100.00	116.11	175.34	226.11	390.48
	e) Depreciation & Amortisation	76.59	208.32	12.08	284.91	355.37	2008.27
	f) Other Expenditure	1405.22	6561.19	850.67	7966.41	8935.29	14148.69
	g) Total	240.08	1871.80	(455.71)	2111.88	2114.26	2061.90
3	Profit from Operations before Other Inc	15.13	11.98	17.52	27.11	21.15	84.64
4	Other Income	255.22	1883.77	(438.19)	2138.99	2135.41	2146.54
5	Profit before Interest & Other Items	175.31	234.28	246.59	409.59	415.78	623.09
6	Finance Costs	79.91	1649.49	(684.78)	1729.40	1719.63	1523.45
7	Profit before Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
8	Exceptional Items	79.91	1649.49	(684.78)	1729.40	1719.63	1523.45
9	Profit/(Loss) before Tax	0.00	0.00	0.00	0.00	0.00	104.82
10	Tax expense	79.91	1649.49	(684.78)	1729.40	1719.63	1418.63
11	Net Profit / (Loss) after Tax	0.08	0.00	1.83	0.08	1.83	1.88
12	Extraordinary Items	79.83	1649.49	(686.61)	1729.32	1717.80	1416.75
13	Net Profit / (Loss) for the period	0.00	0.00	0.00	0.00	0.00	0.00
14	Share of Profit/(Loss) of Associates	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest	79.83	1649.49	(686.61)	1729.32	1717.80	1416.75
16	Net Profit/(Loss) after Associates	1600.40	1600.40	1600.40	1600.40	1600.40	1600.40
17	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	12259.32	12179.49	10831.05	12259.32	10831.05	10530.00
18	Reserves (excluding Revaluation)	0.50	10.31	(4.29)	10.81	10.73	8.85
19	Basic and Diluted EPS						
Particulars of Shareholding							
Public Shareholding							
No of Shares		7779456	7779456	8799899	7779456	8799899	7779456
% of Shareholding		48.61	48.61	54.99	48.61	54.99	48.61
Promoters and Promoter group							
a) Pledged/Encumbered							
No of Shares		6665287	6665287	4420287	6665287	4420287	5920287
% of Shares (as a % of the total shareholding of promoter and promoter capital of the Company)		81.04	81.04	61.36	81.04	61.36	71.98
b) Non Encumbered							
No of Shares		1559257	1559257	2783814	1559257	2783814	2304257
% of Shares (as a % of the total shareholding of promoter and promoter capital of the Company)		18.96	18.96	38.64	18.96	38.64	28.02
% of Shares (as a % of the total shareholding of promoter and promoter capital of the Company)		9.74	9.74	17.39	9.74	17.39	14.40

NOTES : (1) Above financial results were taken on record by the Board of Directors in their meeting held on 14th November 2016. (2) The company is dealing in one major product segment. (3) Investor complaints - Opening Balance - 0, Received and Solved - 2, Closing Balance - 0 (4) The earlier period figures have been regrouped / rearranged where necessary.

FOR NATH BIO-GENES (INDIA) LTD

Satish Kagiwal
Satish Kagiwal
MANAGING DIRECTOR
DIN 00119601

Place : Aurangabad
Date : 14 November 2016

Regd. Office : Nath House, Nath Road, Aurangabad - 431005 (MS)
www.nathbiogenes.com

FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

Gautam Nandawat
GAUTAM NANDAWAT
(Partner)



Nath Bio-Genes (India) Limited
Standalone Statement of Assets and Liabilities

Rs. In Lacs

Particulars	As at 30.09.2016 (Unaudited)	As at 31.03.2016 (Audited)
A EQUITIES AND LIABILITIES		
1. Shareholders' Fund		
(a) Share capital	1600.40	1600.40
(b) Reserves and Surplus	12259.30	10530.00
(c) Money received against share warrants	0.00	0.00
Sub-total - Shareholders' Fund	13859.70	12130.40
2. Share application money pending for allotment	0.00	0.00
3. Minotiries Interest	0.00	0.00
4. Non-current liabilities		
a) Long Term Borrowings	1500.00	1500.00
b) Deferred Tax Liabilities	0.00	0.00
c) Other Long Term Liabilities	0.00	0.00
d) Long Term Provisions	196.23	178.64
Sub-total - Non-current liabilities	1696.23	1678.64
5. Current Liabilities		
a) Short Term Borrowings	4812.26	4304.48
b) Trade Payables	4989.06	4795.13
c) Other Current Liabilities	1760.96	3540.21
d) Short Term Provisions	223.56	221.15
Sub-total - Current liabilities	11785.84	12860.97
TOTAL - EQUITY AND LIABILITIES	27341.77	26670.01
B ASSETS		
(1) Non Current Assets		
a) Fixed Assets	2870.39	3046.36
b) Non Current Investments	0.26	0.26
c) Deferred Tax Assets (Net)	86.86	86.86
d) Long Term Loans and Advances	1129.98	1009.51
e) Other Non Current Assets	0.00	0.00
Sub-total - Non Current Assets	4087.49	4142.99
(2) Current Assets		
a) Current Investments	499.40	499.40
b) Inventories	12973.73	14073.98
c) Trade Receivables	5059.82	4531.14
d) Cash and Cash Equivalents	66.68	122.44
e) Short Term Loans and Advances	4547.01	3184.75
f) Other Current Assets	107.64	115.31
Sub-total - Current Assets	23254.28	22527.02
TOTAL ASSETS	27341.77	26670.01

0.00 0

FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

Gautam N. Dawat
GAUTAM N. DAWAT
(Partner)



FOR NATH BIO-GENES (INDIA) LTD

Satish Kagliwal

Satish Kagliwal
MANAGING DIRECTOR
DIN 00119601